# Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

> **NCT04810611** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** MBG453
- **DRUG:** NIS793
- **DRUG:** canakinumab

## Key facts

- **NCT ID:** NCT04810611
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-18
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810611, "Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04810611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*